Citations

Clear

9 citation(s) found for "Day, John".

Phase II trial of Voyager-V1 (vesicular stomatitis virus expressing human IFNβ and NIS, VV1), in combination with cemiplimab (C) in patients with NSCLC, melanoma, HCC or endometrial carcinoma.
Adjei, Alex A. , Powell, Steven , Pandya, Naimish, Kaesshaefer, Stephen, Reckner, Monica, Brown, Cheryl, Díaz, Rosa María, Russell, Luke, Peng, Kah Whye, Wiegert, Erol , Seebach, Frank, Lowy, Israel , Bexon, Alice, Lutzky, Jose , He, Aiwu Ruth , Patel, Manish R. , O'Day, Steven J , Gullo, Giuseppe

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: TPS3161-TPS3161

10.1200/jco.2020.38.15_suppl.tps3161 Get It

TPS3161 Background: VV1 is an oncolytic vesicular stomatitis virus engineered to express human IFNβ to enhance cellular anti-tumor immune responses and tumor selectivity, and the human sodium iodide symporter (NIS) for virus tracking by SPECT imaging. Cancer cells are often hyporesponsive to IFNβ, enabling the efficient spread of VV1 and resulting in increased oncolysis. Differently from other oncolytic viruses, VV1 is suitable for both intra-tumoral (IT) and/or intra-venous (IV) administration. Despite considerable anti-tumor activity with checkpoint inhibitors (CPI) among some malignancies, long term survival and overall cures remain elusive. Prior Ph 1 studies have shown significant anti-tumor activity among several malignancies when VV1 was administered either as monotherapy or in combination with a CPI, despite progression on prior CPI monotherapy. Furthermore, pre- and post-treatment biopsy evaluations after VV1 treatment have demonstrated T cell infiltration and inflammation in both IT injected and non-injected lesions. Among IV treated patients (pts), IFNβ was detectable in the serum correlating with viral replication, making it an effective biomarker. C is a high-affinity potent human IgG4 anti-PD-1 monoclonal antibody. Though approved for use in cutaneous squamous cell carcinoma, C has shown anti-tumor activity, similar to other CPI, in several other indications. Therefore, VV1 and C could be an attractive combination for the immunotherapy for several solid tumors. This study represents the first clinical evaluation of VV1 in combination with C in pts with advanced solid tumors. Methods: The Ph 2 Simon 2 stage five-arm study of IV administration VV1 in combination with IV C will enroll pts with advanced NSCLC, HCC, melanoma & endometrial cancer. Enrolled pts with NSCLC & melanoma will be recent CPI-progressors, whereas enrolled HCC & endometrial cancer will be CPI-naïve. The study’s objectives include assessment of preliminary anti-tumor activity, safety, & immuno-regulatory activity of the combination. Pts will receive IV VV1 once on D1 and IV C once every 3 weeks until confirmed disease progression or intolerable toxicity. Pts enrolled in one melanoma cohort will also receive IT VV1 administered to palpable lesions. Response will be assessed every 9 weeks per RECIST v1.1. The null hypothesis of each cohort’s ORR will be tested versus a one-sided alternative yielding a Type I error rate of 5% and power of 80%. Cohorts will be expanded based on signal of activity. Clinical trial information: NCT .
Metacommunication process during a 3-day digital storytelling workshop for patients recovering from hematopoietic cell transplantation
Kim, Wonsun, Davis, Olga Idriss , Langer, Shelby L. , Suh, Bin C. , Hoffmann, Nicole, Thakur, Ramesh Devi, Khera, Nandita , Kim, Sunny , Kim, Wonsun, Larkey, Linda

Mayo Clinic

Narrative Inquiry | March 2, 2020 | Volume: 31 | Issue: 2 | Pages: 358-380

10.1075/ni.19036.kim Get It

Abstract Purpose: The purpose of this study was to qualitatively analyze metacommunication during the digital storytelling (DST) workshop process for patients undergoing hematopoietic cell transplantation (HCT). Methods: HCT survivors who had undergone transplant within the past 2 years were recruited at a cancer center in the Phoenix Metropolitan area. Participants (M age = 51.5 years) attended a 3-day DST workshop telling and creating digital stories around their HCT experiences. Using a constructivist grounded theory approach, line by line coding and content analysis were conducted with four research team members. Results: Four themes emerged from the data: (1) communal connection; (2) expressing and processing emotions; (3) self-empowerment; and (4) multi-dimensional coping. Participants described telling and sharing their story with other HCT patients as therapeutic. Conclusion: DST shows promise as a potential coping tool and offers multiple dimensions of the role of narrative as a coping technique, in community building, and in patient-centered contexts within HCT.
Development of a Dual Monoclonal Antibody Immunoassay for Total Human Kallikrein 2
Finlay, Judith A., Day, John, Evans, Cindy L., Carlson, Robert E., Kuus-Reichel, Kristine, Millar, Lisa S., Mikolajczyk, Stephen D., Goodmanson, Marcia K., Klee, George G., Rittenhouse, Harry G.

Mayo Clinic

Clinical Chemistry | January 23, 2020 | Volume: 47 | Issue: 7 | Pages: 1218-1224

10.1093/clinchem/47.7.1218 Get It

AbstractBackground: Human kallikrein 2 (hK2) shares 80% sequence identity with prostate-specific antigen (PSA). Because both hK2 and hK2-α1-antichymotrypsin (hK2-ACT) complexes have been identified in patient sera, we devised an immunoassay for total hK2 [(thK2); hK2 and hK2-ACT] and evaluated it in healthy subjects and patients with prostate disease.Methods: We developed monoclonal antibodies (mAbs) with high specificity for hK2 and hK2-ACT and minimal cross-reactivity to PSA. Using these mAbs, a sandwich assay was developed and its specificity for forms of hK2 was assessed. Serum samples (n = 1035) from healthy volunteers, patients with increased PSA, and men who had undergone radical prostatectomy were assayed for thK2. We also measured thK2 in samples before and after storage under common laboratory conditions.Results: The minimum detectable concentration in the thK2 assay was 0.008 μg/L, and PSA cross-reactivity was <0.001%. The assay detected prohK2 and three different hK2–serum protease complexes. The median serum concentration of thK2 in control samples (0.013 μg/L) was significantly lower than the median in samples from patients with increased PSA concentrations (0.085 μg/L). Immunoreactive hK2 changed little in samples stored for up to 1 month at −70 °C.Conclusions: The thK2 assay recognizes all forms of hK2 that have been found in bodily fluids to date.
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation
Calkins, Hugh , Hindricks, Gerhard , Cappato, Riccardo , Kim, Young‐Hoon , Aguinaga, Luis, Akar, Joseph G. , Badhwar, Vinay , Camm, A. John , Chen, Peng‐Sheng , Chen, Shih‐Ann , Chung, Mina K. , Nielsen, Jens Cosedis , Curtis, Anne B. , Davies, D. Wyn, Groot, Natasja M.S. de , Duytschaever, Mattias , Edgerton, James R. , Ellenbogen, Kenneth A. , Ernst, Sabine , Fenelon, Guilherme , Gerstenfeld, Edward P. , Haines, David E. , Haïssaguerre, Michel , Jackman, Warren M. , Jalife, José , Kalman, Jonathan M. , Kautzner, Josef , Kottkamp, Hans , Kuck, Karl Heinz, Kumagai, Koichiro , Lee, Richard, Lewalter, Thorsten , Lindsay, Bruce D., Mansour, Moussa , Michaud, Gregory F., Nakagawa, Hiroshi , Natale, Andrea , Okumura, Ken , Packer, Douglas L. , Reynolds, Matthew R. , Sanders, Prashanthan , Scanavacca, Maurício , Schilling, Richard J. , Tondo, Claudio , Tsao, Hsuan-Ming, Verma, Atul , Wilber, David J. , Reviewers:, Document, Paola, Ângelo Amato Vincenzo de , Kistler, Peter M. , Pisani, Cristiano , Raviele, Antonio , Satomi, Kazuhiro , Stiles, Martin K. , Willems, Stephan , Haı̈ssaguerre, Michel , Packer, Douglas, Verma, Atul , Natale, Andrea , Sanders, Prashanthan , Nielsen, Jens C , de Groot, Natasja M S , Saad, Eduardo , Brugada, Josép , Day, John , d'Avila, Andre , Biase, Luigi Di , Ellinor, Patrick T. , Haissaguerre, Michel , Helm, Robert H. , Hylek, Elaine M. , Macle, Laurent , Marchlinski, Francis E. , Michaud, Gregory F. , Nattel, Stanley , Pokushalov, Evgeny A. , Tsao, Hsuan-Ming, Yamane, Teiichi , Reviewers:, Document, Blomström‐Lundqvist, Carina , Lip, Gregory Y H , Peters, Nicholas Simon , Scanavacca, Maurício , Tondo, Claudio , Ernst, Sabine , Ellenbogen, Kenneth A

Mayo Clinic

EP Europace | January 17, 2018 | Volume: 20 | Issue: 1 | Pages: e1-e160

10.1093/europace/eux274 | PMID 29016840 Get It

2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary
Calkins, Hugh , Hindricks, Gerhard , Cappato, Riccardo , Kim, Young‐Hoon , Aguinaga, Luis, Akar, Joseph G. , Badhwar, Vinay , Camm, A. John , Chen, Peng‐Sheng , Chen, Shih‐Ann , Chung, Mina K. , Nielsen, Jens Cosedis , Curtis, Anne B. , Davies, D. Wyn, Groot, Natasja M.S. de , Duytschaever, Mattias , Edgerton, James R. , Ellenbogen, Kenneth A. , Ernst, Sabine , Fenelon, Guilherme , Gerstenfeld, Edward P. , Haines, David E. , Haïssaguerre, Michel , Jackman, Warren M. , Jalife, José , Kalman, Jonathan M. , Kautzner, Josef , Kottkamp, Hans , Kuck, Karl Heinz, Kumagai, Koichiro , Lee, Richard, Lewalter, Thorsten , Lindsay, Bruce D., Mansour, Moussa , Michaud, Gregory F., Nakagawa, Hiroshi , Natale, Andrea , Okumura, Ken , Packer, Douglas L. , Reynolds, Matthew R. , Sanders, Prashanthan , Scanavacca, Maurício , Schilling, Richard J. , Tondo, Claudio , Tsao, Hsuan-Ming, Verma, Atul , Wilber, David J. , Haı̈ssaguerre, Michel , Packer, Douglas, Verma, Atul , Natale, Andrea , Sanders, Prashanthan , Nielsen, Jens C , de Groot, Natasja M S , Saad, Eduardo , Brugada, Josép , Day, John , d'Avila, Andre , Biase, Luigi Di , Ellinor, Patrick T. , Haissaguerre, Michel , Helm, Robert H. , Hylek, Elaine M. , Macle, Laurent , Marchlinski, Francis E. , Michaud, Gregory F. , Nattel, Stanley , Pokushalov, Evgeny A. , Tsao, Hsuan-Ming, Yamane, Teiichi , Scanavacca, Maurício , Tondo, Claudio , Ernst, Sabine , Ellenbogen, Kenneth A

Mayo Clinic

EP Europace | January 5, 2018 | Volume: 20 | Issue: 1 | Pages: 157-208

10.1093/europace/eux275 | PMID 29016841 Get It

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program
Gangadhar, Tara C., Hwu, Wen-Jen , Postow, Michael A. , Hamid, Omid , Daud, Adil , Dronca, Roxana , Hodi, F. Stephen , Pavlick, Anna C. , Kluger, Harriet M. , Oxborough, Romina P., Yang, Aiming , Gazdoiu, Mihaela, Kush, Debra, Ebbinghaus, Scot, Salama, April K.S. , Daud, Adil I , Hwu, Wen‐Jen , Joseph, Richard W. , O'Day, Steven J

Mayo Clinic

Journal of Immunotherapy | October 12, 2017 | Volume: 40 | Issue: 9 | Pages: 334-340

10.1097/cji.0000000000000186 | PMID 29028788 Get It

KEYNOTE-030 (ClinicalTrials.gov ID, NCT02083484) was a global expanded access program that allowed access to pembrolizumab, an antiprogrammed death 1 antibody, for patients with advanced melanoma before its regulatory approval. Patients with unresectable stage III/IV melanoma that progressed after standard-of-care therapy, including ipilimumab and, if BRAF V600 mutant, a BRAF inhibitor, were eligible to receive pembrolizumab 2 mg/kg every 3 weeks. Response was assessed by immune-related response criteria by investigator review. Adverse events (AEs) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. In the United States, 979 patients enrolled between April and September 2014. Of the 947 evaluable patients, 621 (65.6%) remained on treatment and transitioned to receive commercial pembrolizumab following approval by the Food and Drug Administration, whereas 326 (34.4%) discontinued, most commonly for disease progression (39.6%) or death (26.4%). Objective response rate was 14.5% (95% confidence interval, 12.2%–16.8%) in the treated population (n=947) and 22.1% (95% confidence interval, 18.8%–25.5%) in patients who had ≥1 response assessment reported (n=619). Twelve patients achieved complete response. One hundred eighty-one (19.1%) patients experienced ≥1 treatment-related AE, most commonly general disorders (8.0%), skin/subcutaneous tissue disorders (7.3%), and gastrointestinal disorders (6.4%); 29 (3.1%) patients experienced ≥1 grade 3/4 treatment-related AE. Immune-mediated AEs were also reported. There were no treatment-related deaths. The safety and efficacy observed in this expanded access program were consistent with those previously reported for similar populations and support the use of pembrolizumab for patients with advanced melanoma.
BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma
Kim, Kevin B. , Sosman, Jeffrey A. , Fruehauf, John P. , Linette, Gerald P. , Nguyen, Hoa , Cheverton, Peter, Chen, Daniel S. , Peterson, Amy , Carson, William E. , Markovic, Svetomir N. , McDermott, David F. , Weber, Jeffrey S. , Peterson, Amy , O'Day, Steven J , Carson, William E

Mayo Clinic

Journal of Clinical Oncology | November 29, 2011 | Volume: 30 | Issue: 1 | Pages: 34-41

10.1200/jco.2011.34.6270 | PMID 22124101 Get It

Purpose Metastatic melanoma, a highly vascularized tumor with strong expression of vascular endothelial growth factor, has an overall poor prognosis. We conducted a placebo-controlled, double-blind phase II study of carboplatin plus paclitaxel with or without bevacizumab in patients with previously untreated metastatic melanoma. Patients and Methods Patients were randomly assigned in a two-to-one ratio to carboplatin (area under the curve, 5) plus paclitaxel (175 mg/m 2 ) and bevacizumab (15 mg/kg; CPB) or placebo (CP) administered intravenously once every 3 weeks. Progression-free survival (PFS) was the primary end point. Secondary end points included overall survival (OS) and safety. Results Two hundred fourteen patients (73% with M1c disease) were randomly assigned. With a median follow-up of 13 months, median PFS was 4.2 months for the CP arm (n = 71) and 5.6 months for the CPB arm (n = 143; hazard ratio [HR], 0.78; P = .1414). Overall response rates were 16.4% and 25.5%, respectively (P = .1577). With 13-month follow-up, median OS was 8.6 months in the CP arm versus 12.3 months in the CPB arm (HR, 0.67; P = .0366), whereas in an evaluation 4 months later, it was 9.2 versus 12.3 months, respectively (HR, 0.79; P = .1916). In patients with elevated serum lactate dehydrogenase (n = 84), median PFS and OS were longer in the CPB arm (PFS: 4.4 v 2.7 months; HR, 0.62; OS: 8.5 v 7.5 months; HR, 0.52). No new safety signals were observed. Conclusion The study did not meet the primary objective of statistically significant improvement in PFS with the addition of bevacizumab to carboplatin plus paclitaxel. A larger phase III study will be necessary to determine whether there is benefit to the addition of bevacizumab to carboplatin plus paclitaxel in this disease setting.
Long-Term Outcome After ICD and CRT Implantation and Influence of Remote Device Follow-Up
Saxon, Leslie A. , Hayes, David L. , Gilliam, F. Roosevelt, Heidenreich, Paul A. , Seth, Milan, Meyer, Timothy E. , Jones, Paul W. , Boehmer, John , Day, John

Mayo Clinic

Circulation | November 23, 2010 | Volume: 122 | Issue: 23 | Pages: 2359-2367

10.1161/circulationaha.110.960633 | PMID 21098452 Get It

Background— Outcome data for patients receiving implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy–defibrillator (CRT-D) devices treated outside of clinical trials are lacking. No clinical trial has evaluated mortality after device implantation or after shock therapy in large numbers of patients with implanted devices that regularly transmit device data over a network. Methods and Results— Survival status in patients implanted with ICD and CRT devices across the United States from a single manufacturer was assessed. Outcomes were compared between patients followed in device clinic settings and those who regularly transmit remote data collected from the device an average of 4 times monthly. Shock delivery and electrogram analysis could be ascertained from patients followed on the network, enabling survival after ICD shock to be evaluated. One- and 5-year survival rates in 185 778 patients after ICD implantation were 92% and 68% and were 88% and 54% for CRT-D device recipients. In 8228 patients implanted with CRT-only devices, survival was 82% and 48% at 1 and 5 years, respectively. For the 69 556 ICD and CRT-D patients receiving remote follow-up on the network, 1- and 5-year survival rates were higher compared with those in the 116 222 patients who received device follow-up in device clinics only (50% reduction; P <0.0001). There were no differences between patients followed on or off the remote network for the characteristics of age, gender, implanted device year or type, and economic or educational status. Shock therapy was associated with subsequent mortality risk for both ICD and CRT-D recipients. Conclusions— Survival after ICD and CRT-D implantation in patients treated in naturalistic practice compares favorably with survival rates observed in clinical trials. Remote follow-up of device data is associated with excellent survival, but arrhythmias that result in device therapy in this population are associated with a higher mortality risk compared with patients who do not require shock therapy.
National Center for Biomedical Ontology: Advancing Biomedicine through Structured Organization of Scientific Knowledge
Lewis, Suzanna , Mungall, Chris , Misra, Sima, Westerfield, Monte , Ashburner, Michael , Solbrig, Harold R. , Storey, Margaret‐Anne , Smith, Barry , Day-Richter, John, Noy, Natalya F., Musen, Mark A. , Rubin, Daniel L. , Sim, Ida , Chute, Christopher G. , Mungall, Christopher J

Mayo Clinic

OMICS: A Journal of Integrative Biology | August 10, 2006 | Volume: 10 | Issue: 2 | Pages: 185-198

10.1089/omi.2006.10.185 | PMID 16901225 Get It

The National Center for Biomedical Ontology is a consortium that comprises leading informaticians, biologists, clinicians, and ontologists, funded by the National Institutes of Health (NIH) Roadmap, to develop innovative technology and methods that allow scientists to record, manage, and disseminate biomedical information and knowledge in machine-processable form. The goals of the Center are (1) to help unify the divergent and isolated efforts in ontology development by promoting high quality open-source, standards-based tools to create, manage, and use ontologies, (2) to create new software tools so that scientists can use ontologies to annotate and analyze biomedical data, (3) to provide a national resource for the ongoing evaluation, integration, and evolution of biomedical ontologies and associated tools and theories in the context of driving biomedical projects (DBPs), and (4) to disseminate the tools and resources of the Center and to identify, evaluate, and communicate best practices of ontology development to the biomedical community. Through the research activities within the Center, collaborations with the DBPs, and interactions with the biomedical community, our goal is to help scientists to work more effectively in the e-science paradigm, enhancing experiment design, experiment execution, data analysis, information synthesis, hypothesis generation and testing, and understand human disease. This paper is part of the special issue of OMICS on data standards.